Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure

Clinical Research in Cardiology

Volumn 107, Issue 1, 2018, Pages 76-86

  Bistola, Vasiliki ^a   Simitsis, Panagiotis ^a   Farmakis, Dimitrios ^a   Ikonomidis, Ignatios ^a   Bakosis, Georgios ^a   Triposkiadis, Filippos ^b   Hatziagelaki, Erifili ^a   Lekakis, John ^a   Mebazaa, Alexandre ^c   Parissis, John ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Acute heart failure; In hospital mortality; Mineralocorticoid receptor antagonists; Short term outcome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NITRATE;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; AGED; ARTICLE; ASTHMA; ATRIAL FIBRILLATION; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; NEAREST NEIGHBOR PROPENSITY SCORE; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; SCORING SYSTEM; SHORT COURSE THERAPY; SINUS RHYTHM; SMOKING; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AUSTRALIA; CHI SQUARE DISTRIBUTION; CONVALESCENCE; DRUG EFFECT; EUROPE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITAL MORTALITY; MEXICO; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPENSITY SCORE; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AUSTRALIA; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; MALE; MEXICO; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECOVERY OF FUNCTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85029575146     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-017-1161-7     Document Type: Article

References (39)

1. Bueno H, Ross JS, Wang Y, Chen J, Vidan MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM (2010) Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. Jama 303(21):2141–2147
2. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L, Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure., Eur J Heart Fail 12(3) (2010) 239 – 48
3. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2009) Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 37(4):619–26
4. Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, Bakosis G, Hatziagelaki E, Lekakis J, Mebazaa A, Parissis J (2017) Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 106(5):359–368
5. Miro O, Gil V, Xipell C, Sanchez C, Aguilo S, Martin-Sanchez FJ, Herrero P, Jacob J, Mebazaa A, Harjola VP, Llorens P, Group I.-S.R. (2017) IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. Clin Res Cardiol 106(5):369–378
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart. J (2016)
7. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy C, Young JB (2007) Association between performance measures and clinical outcomes for patients hospitalized with heart failure. Jama 297(1):61–70
8. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy C, Young JB (2007) Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 153(1):82 e1-11
9. Krantz MJ, Havranek EP, Haynes DK, Smith I, Bucher-Bartelson B, Long CS (2008) Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study. J Card Fail 14(4):303–309
10. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P,(2009) B-CONVINCED: beta-blocker CONtinuation Vs. interruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30(18) 2186–2192
11. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH (2012) Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308(20):2097–107
12. Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, Butler J, Pitt B, Clopton P, de Boer RA (2014) Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol 114(5):737–42
13. Vizzardi E, Sciatti E, Bonadei I, D’Aloia A, Tartiere-Kesri L, Tartiere JM, Cohen-Solal A, Metra M (2015) Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. Clin Res Cardiol 104(12):1078–1087
14. Miro O, Muller C, Martin-Sanchez FJ, Bueno H, Mebazaa A, Herrero P, Jacob J, Gil V, Escoda R, Llorens P, Group I.-S.R. (2016) BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. Clin Res Cardiol 105(12):1021–1029
15. Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F, E. Investigators (2013) Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail 15(11):1228–1235
16. Aronson D, Burger AJ (2003) Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 91(2):245–248
17. Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2(4):370–376
18. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE (2006) Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47(4):650–655
19. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, Myoishi M, Okuda H, Ogai A, Okada K, Tsukamoto O, Koyama H, Hori M, Kitakaze M (2005) Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 46(1):113–117
20. Albaghdadi M, Gheorghiade M, Pitt B (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 32(21):2626–2633
21. Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, Kenizou D, Butler J, Zannad F, Rossignol P (2016) Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol 105(6):489–507
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–17
23. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone Post-Acute Myocardial Infarction Heart Failure, I. Survival Study, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321
24. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E.-H.S. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21
25. Rales Investigators (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78(8):902–907
26. Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O’Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM (2015) Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail 3(2):97–107
27. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37(5):1228–1233
28. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111(23):3025–3033
29. Yee KM, Pringle SD, Struthers AD (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37(7):1800–1807
30. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107(20):2559–2565
31. Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, Investigators E (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 11(11):1099–105
32. Metra M, Bettari L, Pagani F, Lazzarini V, Lombardi C, Carubelli V, Bonetti G, Bugatti S, Parrinello G, Caimi L, Felker GM, Dei L (2012) Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol 101(8):663–72
33. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L (2013) E.S.C. Heart Failure Association of the, Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15(10):1173–1184
34. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL (2008) Death in heart failure: a community perspective. Circ Heart Fail 1(2):91–7
35. Guder G, Hammer F, Deutschbein T, Brenner S, Berliner D, Deubner N, Bidlingmaier M, Ertl G, Allolio B, Angermann CE, Fassnacht M, Stork S (2015) Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism. J Card Fail 21(3):208–16
36. Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M, Investigators ET (2014) Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). Am J Cardiol 114(5):743–50
37. Asakura M, Yamamoto H, Asai K, Hanatani A, Hirata K, Hirayakma A, Kimura K, Kobayashi Y, Momomura S, Nakagawa Y, Nishi Y, Saito Y, Satoh Y, Yamada T, Yamashina A, Yasuda S, Yoshikawa T, Kada A, Uesaka H, Kitakaze M, E. Investigators c (2015) Study, rationale and design of the double-blind, randomized, placebo-controlled multicenter trial on efficacy of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER). Cardiovasc Drugs Ther 29(2):179–85
38. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2014) Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med 25(1):67–72
39. Butler J, Konstam MA, Felker M, Kalogeropoulos AP, Givertz MM, Mann DL, Margulies KB, Redfield MM, Semigran MJ, Tang W, Whellan DJ, McNulty SE, Anstrom KJ, Desvigne-Nickens P, Hernandez AF, Braunwald E (2016) Aldosterone targeted neurohormonal combined with natriuresis TherApy in heart failure. (ATHENA-HF) Trial, American Heart Association Scientific Sessions, New Orleans